Sir, We read with interest the report of two cases of thyrotoxicosis apparently resistant to high doses of carbimazole.' In searching for the cause of a poor therapeutic response to antithyroid drugs, several possibilities must be considered. As pointed out by Cooper,2 noncompliance is the most probable cause of treatment failure. In his study, among nine patients referred for nonresponse to high doses of propylthiouracil, only one was finally considered as possibly resistant. However, even if it is unusual, Li et al recently reported a case of true resistance to methimazole confirmed by the determination of serum and intrathyroidal methimazole concentration. 
Oxidative haemolysis after spiramycin
Sir, I report a case of spiramycin-induced acute haemolysis in a glucose-6-phosphate dehydrogenase (G6PD)-deficient patient confirmed by rechallenge.
A 48-year-old-woman was hospitalised with complaints of malaise, weakness, abdominal and lumber pain 24 h after initiation of treatment with oral spiramycin (1 g bid) for fever and symptoms of an upper respiratory tract infection. Eight years previously G6PD A-deficiency was diagnosed, when she suffered from several sulfonamide-and acetanilide-induced haemolytic episodes requiring blood transfusions. The laboratory data were: haemoglobin 7.7 g/dl, haematocrit 22.4%, reticulocyte count 4.5%, whole blood count 12.4 x 109/l, platelet count 224 x 10/Il. The lactate dehydrogenase concentration was markedly elevated (1823 U/1; normal <300). Three days after the spiramycin therapy, she was afebrile but nauseated, icteric, and passing dark urine. The liver was 3 cm below the right costal margain and the spleen was not palpable. Serum total bilirubin was 2.9 mg/dl (normal < 1.0 mg/dl) with preponderant unconjugated bilirubin fraction (2.8 mg/
